The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors
Yıl: 2022 Cilt: 31 Sayı: 3 Sayfa Aralığı: 207 - 215 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2022.85579 İndeks Tarihi: 03-11-2022
The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors
Öz: Objectives: Metastases and primary malignancies are common in the liver. Local ablative applications such as transarterial chemoembolization (TACE), and transarterial radioembolization (TARE) provide minimally invasive and safe treatment in unresectable liver tumors. Early detection of response to treatment prevents unnecessary toxicity and cost in non-responder patients and provides an earlier use of other options that may be effective. This study aimed to identify the role of 18F-fluorothymidine (FLT) positron emission tomography/computed tomography (PET/CT) in the assessment of early response to TACE and TARE treatments in patients with unresectable primary and metastatic liver tumors. Methods: This single-center study included 63 patients who underwent 18F-FLT PET/CT for response evaluation after TACE and TARE. After excluding 20 patients whose data were missing 43 TARE-receiving patients were analyzed. The compatibility of change in semi-quantitative values obtained from the 18F-FLT PET/CT images with the treatment responses detected in 18F-fluorodeoxyglucose PET/CT, CT, and MR images and survival was evaluated. Results: There was no correlation between early metabolic, morphological response, and 18F-FLT uptake pattern, and change in standardized uptake values (SUV) which were ΔSUVmax, ΔSUVmean, ΔSUVpeak., ΔSUVmean, ΔSUVpeak values. There was no significant correlation between 18F-FLT uptake pattern, ΔSUVmax, ΔSUVmean, ΔSUVpeak, and overall survival, progression-free survival (PFS) for the target lobe PFS for the whole-body. The survival distributions for the patients with >30% change in ΔSUVmax and ΔSUVpeak values were statistically significantly longer than the patients with <30% change (p<0.009 and p<0.024, respectively). Conclusion: There was significant longer PFS for target liver lobe in patients with more than 30% decrease in 18F-FLT SUVmax and SUVpeak of the liver lesion in primary and metastatic unresectable liver tumors undergoing TARE.
Anahtar Kelime: Primer ve Metastatik Karaciğer Tümörlü Hastalarda Transarteriyel Radyoembolizasyon ve Kemoembolizasyona Erken Yanıtı Değerlendirmede 18F-FLT PET/BT’nin Rolü
Öz: Amaç: Karaciğer hem metastazların hem de primer malignitelerin sık görüldüğü bir organdır. Transarteriyel kemoembolizasyon (TAKE) ve transarteriyel radyoembolizasyon (TARE) gibi lokal ablatif uygulamalar, rezeke edilemeyen karaciğer tümörlerinde minimal invaziv ve güvenli tedavi sağlar. Tedaviye yanıtın erken tespiti, yanıt vermeyen hastalarda gereksiz toksisiteyi ve maliyeti önlerken etkili olabilecek diğer seçeneklerin daha erken kullanılmasını sağlar. Bu çalışmada, rezeke edilemeyen primer ve metastatik karaciğer tümörlü hastalarda TAKE ve TARE tedavilerine erken yanıtın değerlendirilmesinde 18F-FLT pozitron emisyon tomografisi/bilgisayarlı tomografinin (PET/BT) rolünün belirlenmesi amaçlanmıştır. Yöntem: Tek merkezli bu çalışmaya, TARE ve TAKE tedavileri öncesi ve sonrasında 18F-FLT PET/BT inceleme yapılarak yanıt değerlendirmesi yapılan 63 hasta dahil edilmiştir. Verileri eksik olan 20 hasta dışlanarak 43 TARE alan hasta analiz edilmiştir. 18F-FLT PET/BT görüntülerinden elde edilen semi-kantitatif değerlerdeki değişimin 18F-florodeoksiglukoz PET/BT, BT ve MR görüntülerinde saptanan tedavi yanıtları ile uyumluluğu ve sağkalımlarla ilişkisi araştırılmıştır. Bulgular: Erken metabolik, morfolojik yanıt ile 18F-FLT tutulum paternindeki değişim, ΔSUVmaks, ΔSUVmean, ΔSUVpeak olarak ifade edilen SUV değerlerindeki değişim arasında korelasyon saptanmamıştır. 18F-FLT tutulum paterninde değişim, ΔSUVmaks, ΔSUVmean ve ΔSUVpeak değerleri ile genel sağkalım, tüm vücut ve hedef lob için progresyonsuz sağkalım (PFS) arasında anlamlı ilişki gözlenmemiştir. ΔSUVmaks ve ΔSUVpeak değerlerinde >%30 değişiklik olan hastaların hedef lob için PFS’leri <%30 değişiklik olanlardan istatistiksel olarak anlamlı düzeyde uzun saptanmıştır (sırasıyla; p<0,009 ve p<0,024). Sonuç: TARE uygulanan primer ve metastatik rezektabl olmayan karaciğer tümöründe karaciğer lezyonunun 18F-FLT SUVmaks ve SUVpeak’inde >%30 azalma olan hastalarda hedef karaciğer lobu için daha uzun PFS saptanmıştır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.
- Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684-692.
- Harding JJ, Abou-Alfa GK. Treating advanced hepatocellular carcinoma: how to get out of first gear. Cancer 2014;120:3122-3130.
- Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol 2011;21:294-302.
- Ryan MJ, Willatt J, Majdalany BS, Kielar AZ, Chong S, Ruma JA, Pandya A. Ablation techniques for primary and metastatic liver tumors. World J Hepatol 2016;8:191-199.
- Viñal D, Minaya-Bravo A, Prieto I, Feliu J, Rodriguez-Salas N. Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. Clin Transl Oncol 2022;24:796-808.
- Yu SCH, Hui JW, Li L, Cho CC, Hui EP, Chan SL, Yeo WM. Comparison of chemoembolization, radioembolization, and transarterial ethanol ablation for huge hepatocellular carcinoma (≥10 cm) in tumour response and long-term survival outcome. Cardiovasc Intervent Radiol 2022;45:172-181.
- Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA, Kim HS. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:224- 230.
- Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterolog 2016;151:1155-1163.e2.
- Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-444.
- Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000;87:881-886.
- Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-623.
- Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, Salem R. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007;188:776-783.
- Singh P, Anil G. Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging 2014;13:645-657.
- Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002;29:815-820.
- Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol 2015;2:191-200.
- Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET radiotracers for the imaging of neuroendocrine neoplasms. Curr Treat Options Oncol 2022;23:703-720.
- Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902-909.
- Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-acetate and 18F-fluorodeoxyglucose PET/computed tomography on 90Y microsphere radioembolization for hepatocellular carcinoma. PET Clin 2019;14:459-467.
- Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-1921.
- Sacks A, Peller P, Surasi DS, Chatburn L, Mercier G, Subramaniam R. Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol 2011;197:W256-259.
- Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol 2011;197:W260-265.
- Chalkidou A, Landau DB, Odell EW, Cornelius VR, O’Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 2012;48:3499-3513.
- Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson J. Simplified labeling approach for synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243:843-846.
- Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;41:96S-103S.
- Peck M, Pollack HA, Friesen A, Muzi M, Shoner SC, Shankland EG, Fink JR, Armstrong JO, Link JM, Krohn KA. Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging 2015;59:95-104.
- Contractor K, Challapalli A, Tomasi G, Rosso L, Wasan H, Stebbing J, Kenny L, Mangar S, Riddle P, Palmieri C, Al-Nahhas A, Sharma R, Turkheimer F, Coombes RC, Aboagye E. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. Phys Med Biol 2012;57:3419-3433.
- Mogensen MB, Loft A, Aznar M, Axelsen T, Vainer B, Osterlind K, Kjaer A. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res 2017;7:56.
- Sanghera B, Wong WL, Sonoda LI, Beynon G, Makris A, Woolf D, Ardeshna K. FLT PET-CT in evaluation of treatment response. Indian J Nucl Med 2014;29:65-73.
- Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, Wells JM, Krohn KA. Kinetic analysis of 3’-deoxy-3’-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-282.
- Sharma R, Inglese M, Dubash S, Lu H, Pinato DJ, Sanghera C, Patel N, Chung A, Tait PD, Mauri F, Crum WR, Barwick TD, Aboagye EO. Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using 18F-fluorothymidine PET. J Nucl Med 2020;61:1743-1748.
- Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-5733.
| APA | NAK D, kucuk n, Kır K, Celebioglu E, bilgic s, Hayme S (2022). The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. , 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| Chicago | NAK DEMET,kucuk nuriye ozlem,Kır Kemal Metin,Celebioglu Emre Can,bilgic sadık,Hayme Serhat The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. (2022): 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| MLA | NAK DEMET,kucuk nuriye ozlem,Kır Kemal Metin,Celebioglu Emre Can,bilgic sadık,Hayme Serhat The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. , 2022, ss.207 - 215. 10.4274/mirt.galenos.2022.85579 |
| AMA | NAK D,kucuk n,Kır K,Celebioglu E,bilgic s,Hayme S The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. . 2022; 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| Vancouver | NAK D,kucuk n,Kır K,Celebioglu E,bilgic s,Hayme S The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. . 2022; 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| IEEE | NAK D,kucuk n,Kır K,Celebioglu E,bilgic s,Hayme S "The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors." , ss.207 - 215, 2022. 10.4274/mirt.galenos.2022.85579 |
| ISNAD | NAK, DEMET vd. "The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors". (2022), 207-215. https://doi.org/10.4274/mirt.galenos.2022.85579 |
| APA | NAK D, kucuk n, Kır K, Celebioglu E, bilgic s, Hayme S (2022). The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. Molecular Imaging and Radionuclide Therapy, 31(3), 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| Chicago | NAK DEMET,kucuk nuriye ozlem,Kır Kemal Metin,Celebioglu Emre Can,bilgic sadık,Hayme Serhat The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. Molecular Imaging and Radionuclide Therapy 31, no.3 (2022): 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| MLA | NAK DEMET,kucuk nuriye ozlem,Kır Kemal Metin,Celebioglu Emre Can,bilgic sadık,Hayme Serhat The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. Molecular Imaging and Radionuclide Therapy, vol.31, no.3, 2022, ss.207 - 215. 10.4274/mirt.galenos.2022.85579 |
| AMA | NAK D,kucuk n,Kır K,Celebioglu E,bilgic s,Hayme S The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. Molecular Imaging and Radionuclide Therapy. 2022; 31(3): 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| Vancouver | NAK D,kucuk n,Kır K,Celebioglu E,bilgic s,Hayme S The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. Molecular Imaging and Radionuclide Therapy. 2022; 31(3): 207 - 215. 10.4274/mirt.galenos.2022.85579 |
| IEEE | NAK D,kucuk n,Kır K,Celebioglu E,bilgic s,Hayme S "The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors." Molecular Imaging and Radionuclide Therapy, 31, ss.207 - 215, 2022. 10.4274/mirt.galenos.2022.85579 |
| ISNAD | NAK, DEMET vd. "The Role of 18F-FLT PET/CT in Assessing Early Response to Transarterial Radioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors". Molecular Imaging and Radionuclide Therapy 31/3 (2022), 207-215. https://doi.org/10.4274/mirt.galenos.2022.85579 |
